問題 › 競合が顧客を奪っている › B2B SaaS
競合に案件を失うのはACVの問題よりポジショニングの問題であることが多く、対応は正反対です。 B2B SaaS企業には特有の制約があります。成長率が42%から32%に低下し、収益の60%が最も経済性の悪いセグメントに集中しています。それを価格付けしない限り、純収益維持率は原因不明で変動し続け、セグメント別勝率の議論は意見の域を出ません。
競合に案件を失うのはACVの問題よりポジショニングの問題であることが多く、対応は正反対です。 B2B SaaS企業には特有の制約があります。成長率が42%から32%に低下し、収益の60%が最も経済性の悪いセグメントに集中しています。それを価格付けしない限り、純収益維持率は原因不明で変動し続け、セグメント別勝率の議論は意見の域を出ません。
競合が勝ち始めると、社内で最初に挙げられる説明は常にACVです。それが正しい場合もあります。より多いのは、競合がより狭い約束を選び、その中で勝っているケースです。営業チームには価格が最後の議論に見えるため、ACVの問題のように映ります。
区別が重要なのは、対応が両立しないためです。本当にACVの問題なら、価格を合わせ全体を再価格設定するか、そのセグメントの喪失を受け入れるかです。ポジショニングの問題なら、ACVを合わせると競合の優位性を資金面で支え、自社の粗利益を毀損します。
見分ける方法は地味です。直近20件の失注理由をACVとセグメントで分けて見ることです。ACVの問題はどこにでも現れます。ポジショニングの問題は純収益維持率とユースケース別のCAC paybackに集中します。
この3つが揃うと特徴的です。1つだけでは別のことを示すことが多いです。
✓ あるセグメントまたはユースケースでのみ勝率とACVが低下し、他では安定している
✓ 営業チームが新しい証明やland-and-expandではなく値引き権限を求める
✓ 競合が自社より小さく特定分野に特化している
通常、事態を悪化させる対応です。 ACVに合わせつつポジショニングを維持し、粗利益と主張の両方を同時に失うこと。
It is for you if you run or finance a B2B SaaS company and losses concentrate in one segment or one use case rather than spreading evenly. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on B2B SaaS企業. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is TechNova Solutions, a sample company profile used for testing rather than a customer — $45M ARR, 280 engineers.
Excerpt from a real Percision run · Cost Reduction & Efficiency · sample company profile
The move. Turn the 11-week implementation backlog into 50 reusable modules that lift services gross margin from 41 % to 55 % while preserving 23 % win rate.
| Investment required | $3.0-4.2 M total over 36 months |
| Expected return | Base case 3.8× cash-on-cash within 36 months |
| Revenue, year 1 | $47.8-49.2 M ARR |
| Revenue, year 2 | $51.5-54.0 M ARR |
| Revenue, year 3 | $56.0-60.0 M ARR |
| Exit criteria | Strategy abandoned if, by Month 12, template-able rule rate remains below 40 % OR if NRR of pilot cohort falls below 85 %; capital reallocated to Segment 2 analytics bolt-on. |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Competitive Benchmarking & Positioning, one of 29 engagements the platform runs. For B2B SaaS企業 it works through net revenue retention, CAC payback, ACV by segment and gross margin, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 完全なレポートはこちらをご覧ください if you would rather see the depth first.
そのセグメントをその価格で利益を出しつつ提供でき、すでに高く払っている顧客の再価格設定も受け入れる場合に限ります。選択的な合わせは市場が気づいた時点で守れない約束になります。
幅ではなく特定性でです。資金力のある競合はあらゆる面で支出で勝てますが、一つの場所で自社より集中することはできません。約束を狭める方が機能セットを広げるより通常有効です。
正直な答えはタイムラインとコストを伴う製品判断であり、マーケティングの対応ではありません。 damaging な結果は、メッセージングでは埋められないギャップに1年を費やすことです。
Materially, yes. Growth has fallen from 42% to 32% while 60% of revenue sits in the segment with the worst economics — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are net revenue retention, CAC payback, ACV by segment, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on net revenue retention and CAC payback. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית